Search clinical trials for: depocyt

Total 87 results

M.D. Anderson Cancer Center

Recruiting

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

Leukemia

United States
M.D. Anderson Cancer Center

Recruiting

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts

Myelodysplastic Syndromes | Myeloproliferative Chronic Myelomonocytic Leukemia

United States
Masonic Cancer Center, University of Minnesota

Recruiting

Auto Stem Cell Transplant for Lymphoma Patients

Hodgkin Lymphoma | Non-Hodgkin Lymphoma

United States
New York Medical College
Roswell Park Cancer Institute

Recruiting

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (O-ICE)

Diffuse Large B-Cell Lymphoma | Burkitt Lymphoma | Non-Hodgkin Lymphoma | Primary Mediastinal B-cell Lymphoma | CD20+ Lymphoblastic Lymphoma | Follicular Lymphoma, Grade III

United States
M.D. Anderson Cancer Center

Recruiting

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Leukemia

United States
Kyowa Kirin, Inc.

Completed

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

Adult T-cell Leukemia-Lymphoma

United States, United Kingdom, Belgium, France, Brazil, Peru
Massachusetts General Hospital
Celgene

Completed

Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia

AML

United States
Kartos Therapeutics, Inc.

Terminated

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

Relapsed or Refractory Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)

United States, Spain, Korea, Republic of, Belgium, United Kingdom, Hungary, France, Germany, Israel, Australia, Italy, Poland
M.D. Anderson Cancer Center

Completed

Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)

Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Alaunos Therapeutics; Intrexon Corporation

Completed

CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies

Lymphoma | B-cell Lymphoma

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital

Active, not recruiting

Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Medical College of Wisconsin

Active, not recruiting

Lintuzumab-Ac225 in Combination With Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
Celgene Corporation; The Leukemia and Lymphoma Society

Completed

Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma

Leukemia

United States
Goethe University

Completed

German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Adult Acute Lymphocytic Leukemia

Germany
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation (M1) | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities and other conditions

United States
Karyopharm Therapeutics Inc

Completed

Selinexor (KPT-330) in Older Patients With Relapsed AML (SOPRA)

Acute Myeloid Leukemia (AML)

Canada, United States, Israel, Netherlands, Denmark, Spain, France, Italy, United Kingdom, Germany, Poland
Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Completed

Autologous Transplant in HIV Patients (BMT CTN 0803)

Lymphoma | HIV

United States
New York Medical College

Completed

Treatment for Advanced B-Cell Lymphoma (REBOOT)

Diffuse Large Cell Lymphoma | Burkitt's Lymphoma | High Grade B-cell Lymphoma

United States
M.D. Anderson Cancer Center
Spectrum Pharmaceuticals, Inc

Completed

Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia

Leukemia

United States
Goethe University

Completed

Treatment of Acute Lymphoblastic Leukemia or Aggressive Lymphoma With Relapse in Central Nervous System With Depocyt

Adult Acute Lymphocytic Leukemia

Germany
University of Aarhus
Mundipharma Pte Ltd.; Roche Pharma AG; Schering-Plough; Nordic Cancer Union

Completed

Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma

Central Nervous System Lymphoma

Denmark
University of California, San Diego
Leadiant Biosciences, Inc.

Terminated

Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

Acute Lymphocytic Leukemia | Adult Lymphoblastic Lymphoma

United States
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Completed

Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia | Leukemia | Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
Amgen

Completed

Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma

Lymphoma

United States
M.D. Anderson Cancer Center

Completed

Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation

Lymphoma | Diffuse Large Cell Lymphoma

United States
M.D. Anderson Cancer Center
Genzyme, a Sanofi Company

Completed

Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)

Acute Myeloid Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center

Completed

Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia

Leukemia | Acute Lymphoblastic Leukemia

United States
M.D. Anderson Cancer Center

Completed

Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies

Lymphoma | Leukemia

United States
M.D. Anderson Cancer Center
Ortho Biotech, Inc.

Completed

Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma

Lymphoma

United States
Masonic Cancer Center, University of Minnesota

Completed

Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

Lymphoma

United States
M.D. Anderson Cancer Center
Genentech, Inc.

Completed

Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger

Lymphoma

United States
Nordic Lymphoma Group
Mundipharma Pte Ltd.; Amgen

Completed

CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis (CHIC)

Primary Disease

Denmark, Finland, Norway, Sweden
M.D. Anderson Cancer Center

Completed

Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome

Leukemia

United States
M.D. Anderson Cancer Center
Eli Lilly and Company; High Impact Clinical Research Support Program

Completed

LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Leukemia

United States
Centre Oscar Lambret

Completed

Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Meningeal Metastasis of Breast Cancer (DEPOSEIN)

Breast Cancer | Leptomeningeal Metastases

France
M.D. Anderson Cancer Center

Completed

Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia

Leukemia

United States
M.D. Anderson Cancer Center
Novartis

Completed

RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia

Leukemia | Acute Lymphocytic Leukemia

United States
Medical University of South Carolina

Terminated

A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma

Glioma | Astrocytoma | Brain Tumor | Glioblastoma Multiforme

United States
Michael Burke
Children's Hospitals and Clinics of Minnesota

Terminated

Epigenetic Reprogramming in Relapse AML

Leukemia, Acute Myeloid

United States
University of Florida
Novartis Pharmaceuticals

Withdrawn

iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
Genzyme, a Sanofi Company

Completed

Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction

Acute Myeloid Leukemia

United States
Lymphoma Study Association

Completed

Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis

Lymphoma, Non-Hodgkin | Diffuse Large B-cell Lymphoma

Belgium, France
M.D. Anderson Cancer Center
Eisai Inc.

Completed

E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes

Leukemia

United States
M.D. Anderson Cancer Center

Completed

Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)

Leukemia | Myeloproliferative Diseases

United States
M.D. Anderson Cancer Center
Jazz Pharmaceuticals

Withdrawn

Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies

Hematologic Malignancy
M.D. Anderson Cancer Center
Jazz Pharmaceuticals

Terminated

Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Lymphoma | Leukemia | Lymphoblastic Lymphoma | Precursor-B Acute Lymphoblastic Leukemia

United States
M.D. Anderson Cancer Center
Cephalon

Completed

Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Leukemia

United States
M.D. Anderson Cancer Center

Completed

Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma

Burkitt's Lymphoma | Burkitt'S-like Lymphoma

United States
Massachusetts General Hospital
Boehringer Ingelheim

Withdrawn

Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia

AML

United States

Search clinical trials for: depocyt

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations